Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company developing prescription drugs targeting rare neuromuscular and neurological diseases and disorders. The company’s principal product is Firdapse, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It also develops CPP-115, a GABA aminotransferase inhibitor for the treatment of epilepsy and other central nervous disease indications; and CPP-109 for the treatment of Tourette Syndrome. For more information, visit the company’s website at www.catalystpharma.com.